logo-loader
HealthPharma & Biotech
viewAbcam

Abcam raises revenue guidance after Roche deal

For the full year, sales guidance has been raised by 11%

antibody
Sales guidance has been raised by 11%

Antibodies supplier Abcam PLC (LON:ABC) has raised its revenue forecasts this year to reflect the benefits a recent deal with Roche

For the full year, sales guidance has been raised by 11% to include the impact of January's Spring Bioscience (Roche) agreement.

READ: Abcam lifts interim dividend as first half revenue is boosted by rabbit antibody

Through that deal, Abcam obtained exclusive rights to approximately 760 unique products.

Interim sales were 10% higher at £112.5mln, profits rose by 30% while the half-year dividend goes up by 21%.

A software upgrade to its warehouse that is taking longer than expected to implement was the only note of caution in an otherwise upbeat statement.

Catalogue sales remain the core of the business and revenues grew by 10% on a reported basis to £105.2mln, with recombinant antibody sales 21% higher at £22.4m.

Immunoassay product revenues grew by 20.7% to £7.0mln.

Profit before tax was £32.8mln (25.1mln), with a 3.42p interim dividend.

Alan Hirzel, chief executive, said: "It has been another good half, delivering double-digit revenue growth while meeting all of our financial and strategic targets.

“We remain on track to meet our strategic goals for the year and we have increased our revenue guidance for the full year.”

Quick facts: Abcam

Price: 1150 GBX

AIM:ABC
Market: AIM
Market Cap: £2.37 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Panther Metals set up for its next strategic move with an 'enviable'...

Panther Metals plc's (LON:PALM) Darren Hazelwood and Kerim Sener introduce the explorer to Proactive London's Andrew Scott. In Canada recent field activities have returned some 'exceptional' results including significant soil gold anomalies in four major target areas. Meanwhile in...

12 hours, 53 minutes ago

RNS

Holding(s) in Company

2 weeks, 1 day ago

Director/PDMR Shareholding

2 weeks, 1 day ago

Total Voting Rights

2 weeks, 2 days ago

Annual Financial Report

2 weeks, 3 days ago

Director/PDMR Shareholding

1 month, 1 day ago

2 min read